| 1 |
Coroadinha AS. Host Cell Restriction Factors Blocking Efficient Vector Transduction: Challenges in Lentiviral and Adeno-Associated Vector Based Gene Therapies. Cells 2023;12. [PMID: 36899868 DOI: 10.3390/cells12050732] [Reference Citation Analysis]
|
| 2 |
Bomb K, Levalley PJ, Woodward IR, Cassel SE, Sutherland BP, Bhattacharjee A, Yun Z, Steen J, Kurdzo E, Mccoskey J, Burris D, Levine K, Carbrello C, Lenhoff AM, Fromen CA, Kloxin AM. Cell Therapy Biomanufacturing: Integrating Biomaterial and Flow‐Based Membrane Technologies for Production of Engineered T‐Cells. Adv Materials Technologies 2023. [DOI: 10.1002/admt.202201155] [Reference Citation Analysis]
|
| 3 |
Braun AH, Frank AM, Ho N, Buchholz CJ. Dasatinib is a potent enhancer for CAR T cell generation by CD3-targeted lentiviral vectors. Mol Ther Methods Clin Dev 2023;28:90-8. [PMID: 36620073 DOI: 10.1016/j.omtm.2022.12.002] [Reference Citation Analysis]
|
| 4 |
Cordes N, Winter N, Kolbe C, Kotter B, Mittelstaet J, Assenmacher M, Cathomen T, Kaiser A, Schaser T. Adapter-Mediated Transduction with Lentiviral Vectors: A Novel Tool for Cell-Type-Specific Gene Transfer. Viruses 2022;14:2157. [PMID: 36298713 DOI: 10.3390/v14102157] [Reference Citation Analysis]
|
| 5 |
Nahmad AD, Lazzarotto CR, Zelikson N, Kustin T, Tenuta M, Huang D, Reuveni I, Nataf D, Raviv Y, Horovitz-Fried M, Dotan I, Carmi Y, Rosin-Arbesfeld R, Nemazee D, Voss JE, Stern A, Tsai SQ, Barzel A. In vivo engineered B cells secrete high titers of broadly neutralizing anti-HIV antibodies in mice. Nat Biotechnol 2022;40:1241-9. [PMID: 35681059 DOI: 10.1038/s41587-022-01328-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 6 |
Dobson CS, Reich AN, Gaglione S, Smith BE, Kim EJ, Dong J, Ronsard L, Okonkwo V, Lingwood D, Dougan M, Dougan SK, Birnbaum ME. Antigen identification and high-throughput interaction mapping by reprogramming viral entry. Nat Methods 2022;19:449-60. [PMID: 35396484 DOI: 10.1038/s41592-022-01436-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 7 |
Scott TA, Supramaniam A, Idris A, Cardoso AA, Shrivastava S, Kelly G, Grepo NA, Soemardy C, Ray RM, McMillan NAJ, Morris KV. Engineered extracellular vesicles directed to the spike protein inhibit SARS-CoV-2. Mol Ther Methods Clin Dev 2022;24:355-66. [PMID: 35127966 DOI: 10.1016/j.omtm.2022.01.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 8 |
Guo XJ, Elledge SJ. V-CARMA: A tool for the detection and modification of antigen-specific T cells. Proc Natl Acad Sci U S A 2022;119:e2116277119. [PMID: 35042811 DOI: 10.1073/pnas.2116277119] [Reference Citation Analysis]
|
| 9 |
Yu B, Shi Q, Belk JA, Yost KE, Parker KR, Huang H, Lingwood D, Davis MM, Satpathy AT, Chang HY. Systematic discovery of receptor-ligand biology by engineered cell entry and single-cell genomics.. [DOI: 10.1101/2021.12.13.472464] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 10 |
Charitidis FT, Adabi E, Thalheimer FB, Clarke C, Buchholz CJ. Monitoring CAR T cell generation with a CD8-targeted lentiviral vector by single-cell transcriptomics. Mol Ther Methods Clin Dev 2021;23:359-69. [PMID: 34729382 DOI: 10.1016/j.omtm.2021.09.019] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 11 |
Michels A, Frank AM, Günther DM, Mataei M, Börner K, Grimm D, Hartmann J, Buchholz CJ. Lentiviral and adeno-associated vectors efficiently transduce mouse T lymphocytes when targeted to murine CD8. Mol Ther Methods Clin Dev 2021;23:334-47. [PMID: 34729380 DOI: 10.1016/j.omtm.2021.09.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 12 |
Asaadi Y, Jouneghani FF, Janani S, Rahbarizadeh F. A comprehensive comparison between camelid nanobodies and single chain variable fragments. Biomark Res 2021;9:87. [PMID: 34863296 DOI: 10.1186/s40364-021-00332-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 13 |
Panigaj M, Marino MP, Reiser J. Tagging and Capturing of Lentiviral Vectors Using Short RNAs. Int J Mol Sci 2021;22:10263. [PMID: 34638603 DOI: 10.3390/ijms221910263] [Reference Citation Analysis]
|
| 14 |
Dobson CS, Reich AN, Gaglione S, Smith BE, Kim EJ, Dong J, Ronsard L, Okonkwo V, Lingwood D, Dougan M, Dougan SK, Birnbaum ME. Antigen identification and high-throughput interaction mapping by reprogramming viral entry.. [DOI: 10.1101/2021.09.18.460796] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 15 |
Page A, Hubert J, Fusil F, Cosset FL. Exploiting B Cell Transfer for Cancer Therapy: Engineered B Cells to Eradicate Tumors. Int J Mol Sci 2021;22:9991. [PMID: 34576154 DOI: 10.3390/ijms22189991] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 16 |
Huckaby JT, Landoni E, Jacobs TM, Savoldo B, Dotti G, Lai SK. Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells. J Immunother Cancer 2021;9:e002737. [PMID: 34518288 DOI: 10.1136/jitc-2021-002737] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 17 |
Frank AM, Braun AH, Scheib L, Agarwal S, Schneider IC, Fusil F, Perian S, Sahin U, Thalheimer FB, Verhoeyen E, Buchholz CJ. Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors. Blood Adv 2020;4:5702-15. [PMID: 33216892 DOI: 10.1182/bloodadvances.2020002229] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
|
| 18 |
Argaw T, Marino MP, Timmons A, Eldridge L, Takeda K, Li P, Kwilas A, Ou W, Reiser J. In vivo targeting of lentiviral vectors pseudotyped with the Tupaia paramyxovirus H glycoprotein bearing a cell-specific ligand. Mol Ther Methods Clin Dev 2021;21:670-80. [PMID: 34141822 DOI: 10.1016/j.omtm.2021.04.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 19 |
Weidner T, Agarwal S, Perian S, Fusil F, Braun G, Hartmann J, Verhoeyen E, Buchholz CJ. Genetic in vivo engineering of human T lymphocytes in mouse models. Nat Protoc 2021;16:3210-40. [PMID: 33846629 DOI: 10.1038/s41596-021-00510-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 20 |
Xu X, Huang S, Xiao X, Sun Q, Liang X, Chen S, Zhao Z, Huo Z, Tu S, Li Y. Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments. Front Immunol 2020;11:569117. [PMID: 33643279 DOI: 10.3389/fimmu.2020.569117] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 21 |
Scher G, Schnell MJ. Rhabdoviruses as vectors for vaccines and therapeutics. Curr Opin Virol 2020;44:169-82. [PMID: 33130500 DOI: 10.1016/j.coviro.2020.09.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 22 |
Chicaybam L, Bonamino MH, Luckow Invitti A, Bortman Rozenchan P, de Luna Vieira I, Strauss BE. Overhauling CAR T Cells to Improve Efficacy, Safety and Cost. Cancers (Basel) 2020;12:E2360. [PMID: 32825533 DOI: 10.3390/cancers12092360] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 23 |
Morgan MA, Büning H, Sauer M, Schambach A. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells. Front Immunol 2020;11:1965. [PMID: 32903482 DOI: 10.3389/fimmu.2020.01965] [Cited by in Crossref: 51] [Cited by in F6Publishing: 55] [Article Influence: 17.0] [Reference Citation Analysis]
|
| 24 |
Li Y, Chen Y, Mao S, Kaundal R, Jing Z, Chen Q, Wang X, Xia J, Liu D, Sun J, Wang H, Chi T. In situ conversion of defective Treg into SuperTreg cells to treat advanced IPEX-like disorders in mice. Nat Commun 2020;11:2781. [PMID: 32493900 DOI: 10.1038/s41467-020-15836-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 25 |
Agarwal S, Hanauer JDS, Frank AM, Riechert V, Thalheimer FB, Buchholz CJ. In Vivo Generation of CAR T Cells Selectively in Human CD4+ Lymphocytes. Mol Ther 2020;28:1783-94. [PMID: 32485137 DOI: 10.1016/j.ymthe.2020.05.005] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 26 |
Frank AM, Weidner T, Brynza J, Uckert W, Buchholz CJ, Hartmann J. CD8-Specific Designed Ankyrin Repeat Proteins Improve Selective Gene Delivery into Human and Primate T Lymphocytes. Hum Gene Ther 2020;31:679-91. [PMID: 32160795 DOI: 10.1089/hum.2019.248] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 27 |
Breuer CB, Hanlon KS, Natasan JS, Volak A, Meliani A, Mingozzi F, Kleinstiver BP, Moon JJ, Maguire CA. In vivo engineering of lymphocytes after systemic exosome-associated AAV delivery. Sci Rep 2020;10:4544. [PMID: 32161326 DOI: 10.1038/s41598-020-61518-w] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 28 |
Shirley JL, de Jong YP, Terhorst C, Herzog RW. Immune Responses to Viral Gene Therapy Vectors. Mol Ther 2020;28:709-22. [PMID: 31968213 DOI: 10.1016/j.ymthe.2020.01.001] [Cited by in Crossref: 207] [Cited by in F6Publishing: 157] [Article Influence: 69.0] [Reference Citation Analysis]
|
| 29 |
Shinde P, Kumar A, Kavitha, Dey K, Mohan L, Kar S, Barik TK, Sharifi-rad J, Nagai M, Santra TS. Physical approaches for drug delivery. Delivery of Drugs 2020. [DOI: 10.1016/b978-0-12-817776-1.00007-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 30 |
Wang Y, Li S, Tian Z, Sun J, Liang S, Zhang B, Bai L, Zhang Y, Zhou X, Xiao S, Zhang Q, Zhang L, Zhang C, Zhou D. Generation of a caged lentiviral vector through an unnatural amino acid for photo-switchable transduction. Nucleic Acids Res 2019;47:e114. [PMID: 31361892 DOI: 10.1093/nar/gkz659] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 31 |
Brendel C, Rio P, Verhoeyen E. Humanized mice are precious tools for evaluation of hematopoietic gene therapies and preclinical modeling to move towards a clinical trial. Biochem Pharmacol 2020;174:113711. [PMID: 31726047 DOI: 10.1016/j.bcp.2019.113711] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 32 |
Coquin Y, Ferrand M, Seye A, Menu L, Galy A. Syncytins enable novel possibilities to transduce human or mouse primary B cells and to achieve well-tolerated in vivo gene transfer.. [DOI: 10.1101/816223] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 33 |
Li Y, Chi T. A reversible KO model reveals therapeutic potentials of defective Tregs.. [DOI: 10.1101/770347] [Reference Citation Analysis]
|
| 34 |
Hartmann J, Thalheimer FB, Höpfner F, Kerzel T, Khodosevich K, García-González D, Monyer H, Diester I, Büning H, Carette JE, Fries P, Buchholz CJ. GluA4-Targeted AAV Vectors Deliver Genes Selectively to Interneurons while Relying on the AAV Receptor for Entry. Mol Ther Methods Clin Dev 2019;14:252-60. [PMID: 31463334 DOI: 10.1016/j.omtm.2019.07.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 35 |
Mhaidly R, Verhoeyen E. The Future: In Vivo CAR T Cell Gene Therapy. Mol Ther 2019;27:707-9. [PMID: 30914238 DOI: 10.1016/j.ymthe.2019.03.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 36 |
Jamali A, Kapitza L, Schaser T, Johnston ICD, Buchholz CJ, Hartmann J. Highly Efficient and Selective CAR-Gene Transfer Using CD4- and CD8-Targeted Lentiviral Vectors. Mol Ther Methods Clin Dev 2019;13:371-9. [PMID: 30997367 DOI: 10.1016/j.omtm.2019.03.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 37 |
Pan D, Büning H, Ling C. Rational Design of Gene Therapy Vectors. Mol Ther Methods Clin Dev 2019;12:246-7. [PMID: 30815510 DOI: 10.1016/j.omtm.2019.01.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
